Steven L. Abrams

1.3k total citations · 1 hit paper
9 papers, 1.0k citations indexed

About

Steven L. Abrams is a scholar working on Molecular Biology, Organic Chemistry and Pathology and Forensic Medicine. According to data from OpenAlex, Steven L. Abrams has authored 9 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 2 papers in Organic Chemistry and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Steven L. Abrams's work include PI3K/AKT/mTOR signaling in cancer (4 papers), Melanoma and MAPK Pathways (4 papers) and Protein Kinase Regulation and GTPase Signaling (3 papers). Steven L. Abrams is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (4 papers), Melanoma and MAPK Pathways (4 papers) and Protein Kinase Regulation and GTPase Signaling (3 papers). Steven L. Abrams collaborates with scholars based in United States, Italy and Germany. Steven L. Abrams's co-authors include James A. McCubrey, Linda S. Steelman, Massimo Libra, Franca Stivala, Richard A. Franklin, David M. Terrian, Patrick M. Navolanic, Fred E. Bertrand, Fumin Chang and Jeffrey L. Salisbury and has published in prestigious journals such as Blood, Oncogene and Leukemia.

In The Last Decade

Steven L. Abrams

9 papers receiving 1.0k citations

Hit Papers

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in ma... 2006 2026 2012 2019 2006 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance
    2006 550 citations James A. McCubrey, Linda S. Steelman et al. Advances in Enzyme Regulation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Steven L. Abrams United States 8 711 340 180 149 123 9 1.0k
Melissa Dumble United States 17 749 1.1× 411 1.2× 244 1.4× 91 0.6× 145 1.2× 28 1.3k
Rhoda Arzoomanian United States 15 510 0.7× 319 0.9× 160 0.9× 139 0.9× 148 1.2× 27 947
Shigeru Tomoyasu Japan 22 718 1.0× 356 1.0× 148 0.8× 250 1.7× 99 0.8× 90 1.3k
Clara Campàs Spain 16 773 1.1× 385 1.1× 211 1.2× 114 0.8× 131 1.1× 20 1.2k
Wenqing Qi United States 20 668 0.9× 370 1.1× 83 0.5× 135 0.9× 126 1.0× 42 1.0k
Daniel Iglesias‐Serret Spain 20 741 1.0× 306 0.9× 133 0.7× 105 0.7× 54 0.4× 32 1.0k
Bojie Dai United States 18 697 1.0× 194 0.6× 193 1.1× 142 1.0× 264 2.1× 30 1.1k
Mike I. Walton United Kingdom 7 630 0.9× 283 0.8× 118 0.7× 112 0.8× 91 0.7× 9 856
Mary M. Vaughan United States 17 497 0.7× 370 1.1× 224 1.2× 81 0.5× 120 1.0× 27 1.0k
Tomohiko Sakabe Japan 17 475 0.7× 248 0.7× 197 1.1× 60 0.4× 98 0.8× 43 991

Countries citing papers authored by Steven L. Abrams

Since Specialization
Citations

This map shows the geographic impact of Steven L. Abrams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven L. Abrams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven L. Abrams more than expected).

Fields of papers citing papers by Steven L. Abrams

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven L. Abrams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven L. Abrams. The network helps show where Steven L. Abrams may publish in the future.

Co-authorship network of co-authors of Steven L. Abrams

This figure shows the co-authorship network connecting the top 25 collaborators of Steven L. Abrams. A scholar is included among the top collaborators of Steven L. Abrams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven L. Abrams. Steven L. Abrams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
McCubrey, James A., Linda S. Steelman, Steven L. Abrams, et al.. (2010). Emerging MEK inhibitors. Expert Opinion on Emerging Drugs. 15(2). 203–223. 48 indexed citations
2.
McCubrey, James A., Linda S. Steelman, Steven L. Abrams, et al.. (2009). Emerging Raf inhibitors. Expert Opinion on Emerging Drugs. 14(4). 633–648. 26 indexed citations
3.
McCubrey, James A., Linda S. Steelman, Steven L. Abrams, et al.. (2008). Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia. 22(4). 708–722. 189 indexed citations
4.
Steelman, Linda S., Patrick M. Navolanic, Melissa L. Sokolosky, et al.. (2008). Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene. 27(29). 4086–4095. 130 indexed citations
5.
McCubrey, James A., Linda S. Steelman, Richard A. Franklin, et al.. (2007). Targeting the RAF/MEK/ERK, PI3K/AKT and P53 pathways in hematopoietic drug resistance. Advances in Enzyme Regulation. 47(1). 64–103. 67 indexed citations
6.
McCubrey, James A., Linda S. Steelman, Steven L. Abrams, et al.. (2006). Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Advances in Enzyme Regulation. 46(1). 249–279. 550 indexed citations breakdown →
7.
McCubrey, James A., Steven L. Abrams, Linda S. Steelman, et al.. (2006). Dominant Role of Raf/MEK/ERK Signaling in Hematopoietic Cell Cycle Progression, Prevention of Apoptosis and Drug Resistance.. Blood. 108(11). 1116–1116. 1 indexed citations
8.
Shelton, John G., Linda S. Steelman, Steven L. Abrams, et al.. (2005). Conditional EGFR Promotes Cell Cycle Progression and Prevention of Apoptosis in the Absence of Autocrine Cytokines. Cell Cycle. 4(6). 822–830. 23 indexed citations
9.
Shelton, John G., Linda S. Steelman, Steven L. Abrams, et al.. (2005). Effects of Endogenous Epidermal Growth Factor Receptor Signaling on DNA Synthesis and ERK Activation in a Cytokine-Dependent Hematopoietic Cell Line. Cell Cycle. 4(6). 818–821. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Melissa Dumble Breakdown of academic impact, for papers by Rhoda Arzoomanian Breakdown of academic impact, for papers by Shigeru Tomoyasu Breakdown of academic impact, for papers by Clara Campàs Breakdown of academic impact, for papers by Wenqing Qi Breakdown of academic impact, for papers by Daniel Iglesias‐Serret Breakdown of academic impact, for papers by Bojie Dai Breakdown of academic impact, for papers by Mike I. Walton Breakdown of academic impact, for papers by Mary M. Vaughan Breakdown of academic impact, for papers by Tomohiko Sakabe
Rankless by CCL
2026